Behind the science
Is prevention the ‘medicine’ we need to end the HIV epidemic?
Scientists and advocates at the forefront of the race to end the HIV/AIDS epidemic by 2030 reflect on how far new innovations in preventative healthcare - and barrier-breaking strategies that put people first - can take us.
Our purpose
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology
Behind the science
Discover how we're getting ahead
‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
‘Patients can breathe easier today’: Scientific advances in asthma and COPD care could prevent irreversible lung damage
Robots, AI, and machine learning: how smart manufacturing is getting medicines and vaccines from factories to patients faster
'Prevention is the best medicine to stop disease before it starts'
‘Global health progress is vital for millions of lives, but it isn’t going fast enough. Here’s what we need to do to get things back on track’
‘You can’t be what you can’t see’: Why diversity in STEM is key to greater medical innovation
The ‘tripledemic’ will hit older people hard this winter – but there are things we can all do to reduce the impact
Outstanding people
WORKING TOGETHER
Meet Andy: how a life-changing diagnosis changed his career
MY GSK STORY
Meet Katie: elevating the voice of the patient
WORKING TOGETHER
Meet Mark and Giuseppe: working to reduce our carbon footprint
MY GSK STORY
Meet Dana: representing the voices of indigenous colleagues
MY GSK STORY
Meet Samuel: helping get medicines to our patients
MY GSK STORY
Meet Alison: taking pride in working for GSK